Loading, please wait....jpg)
.jpg)
CONTINUING PHARMACY EDUCATION
Incorporating Anti-Amyloid-B (AB) Monoclonal Antibody Therapies into Alzheimer’s Disease Management
Speaker: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Dean and Professor, Pacific University School of Pharmacy, Hillboro, OR
ACPE Universal Program ID# 0122-0000-25-078-H01-T
1 Contact Hours [0.1 CEU]
Release Date: November 3, 2025
Expiration Date: November 3, 2028
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Discuss currently available pharmacologic treatments for Alzheimer’s disease
- Describe the benefits of the current available treatments for Alzheimer's Disease, including anti-amyloid-B monoclonal antibodies
- Identify the type of patient that may be eligible to receive anti-amyloid-B monoclonal antibody treatment options
- List common adverse effects of anti-amyloid-B monoclonal antibodies for Alzheimer's disease
Speaker(s)/Author(s)
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
|
Activity Number
0122-0000-25-078-H01-T
Release Date:
Nov 3, 2025
Credit Expiration Date:
Nov 3, 2028
CE Hours
1.00